智翔金泰：预计2025年净利润亏损4.81亿元-5.87亿元

Core Viewpoint - Zhixiang Jintai (688443.SH) expects a net loss attributable to shareholders of 481 million to 587 million yuan for 2025, primarily due to increased sales revenue from its first commercial product, Sailiqi monoclonal antibody injection, and recognition of licensing income from GR1803 injection [1] Financial Performance - The anticipated net loss for 2025 is projected to be between 481 million yuan and 587 million yuan [1] - The performance fluctuation is attributed to the growth in sales revenue from the commercialized product and the confirmation of licensing income [1] Cost Management - The company will not incur share-based payment expenses in 2025 due to the expiration of the stock incentive service period [1] - Research and development expenses are expected to decrease year-on-year [1]